News Releases

Date Title and Summary View
March 10, 2020
– Oral Hereditary Angioedema Franchise Phase 2 Clinical Trials on Track – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule...
Additional Formats
February 19, 2020
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 19, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...
Additional Formats
February 10, 2020
– Merck Option Agreement Expires – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Feb. 10, 2020-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,...
Additional Formats
January 13, 2020
– KVD900 Phase 2 Clinical Trial Data Anticipated in Q2 2020 – – KVD824 Selected for Prophylactic Treatment; Phase 2 Expected to Initiate in H2 2020 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jan. 13, 2020-- KalVista Pharmaceuticals, Inc....
Additional Formats